OUr pipeline
program
Target(s)
Indication
Discovery
Lead Optimization
IND enabling
phase 1
RNDO-564
CD28 x Nectin-4
Bladder Cancer
RNDO-Program 2
CD3 x TAA-1
CD28 x TAA-2
Ovarian Cancer
RNDO-Program 3
Undisclosed
Undisclosed
RNDO-564
RNDO-Program 2
RNDO-Program 23
BlaDDER CANCER
Bladder cancer accounts for 6% of current cancer diagnoses in the US. Up to 50% of patients with muscle invasive bladder cancer develop metastases following surgery for localized disease with 5-year survival rates of less than 10%. The approval of Nectin-4 ADC and checkpoint inhibitor combinations has significantly improved the treatment landscape for patients. However, there are patients who either relapse or cannot tolerate payload related toxicities, leaving a significant unmet need and an opportunity to treat patients with an alternative therapeutic modality.
Our most advanced program, RNDO-564, is a novel, fully-human bispecific antibody that binds CD28 and Nectin-4, a clinically validated tumor target for bladder cancer. Based on pre-clinical models, we believe that RNDO-564 will deliver robust, single-agent anti-tumor responses. Many patients with metastatic bladder cancer have tumor-specific T-cells with activated endogenous Signal 1 but insufficient sustained activity. RNDO-564 safely provides T-cells an extra boost of tumor-killing co-stimulation through CD28.
Minimal on-target, off-tumor activity: Higher Nectin-4 affinity relative to CD28 drives RNDO-564 localization to the tumor, eliciting potent anti-tumor activity only in the presence of Nectin-4. Furthermore, we have optimized the CD28 binding arm of RNDO-564 so that it is inactive in healthy tissues.
OVARIAN
Most ovarian cancer patients present with advanced disease at diagnosis, and despite high responses to initial treatment, the majority relapse with incurable disease. Five-year survival rates remain poor. The current standard of care for late stage ovarian cancer includes chemotherapy, PARP inhibitors, and ADCs, leaving room for novel immunotherapy approaches.
Rondo Therapeutics believes a bispecific combination will provide clinicians the ability to safely activate and co-stimulate tumor infiltrating T-cells and promote robust immune-mediated tumor killing. We are developing two novel bispecific antibodies (CD3 x TAA-1 and CD28 x TAA-2), each targeting a different tumor antigen to enhance specificity and efficacy.
